Form 4: MariMed Inc. Executive Reports Stock Transactions

MariMed Inc. Chief Commercial Officer Ryan Crandall reports transactions involving restricted stock units and common stock.

Summary

• Ryan Crandall, Chief Commercial Officer of MariMed Inc., has reported transactions related to his beneficial ownership of the company's stock.
• On May 29, 2026, 37,500 restricted stock units (RSUs) were acquired, converting to common stock at a price of $0.00.
• Additionally, 12,994 shares of common stock were disposed of on the same date, with a transaction price of $0.0805 per share, to cover tax withholding obligations related to RSU vesting.
• Following these transactions, Crandall beneficially owns 904,140 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine insider transactions related to equity compensation and tax obligations, rather than a significant strategic move or performance indicator.

Positives

• The acquisition of 37,500 RSUs indicates continued equity incentive for key management.
• The reporting person maintains a significant direct beneficial ownership of 904,140 shares of common stock, suggesting alignment with shareholder interests.

Negatives

• 12,994 shares of common stock were disposed of to cover tax withholding obligations, representing a reduction in directly held shares.

Future Outlook

The remaining Restricted Stock Units are scheduled to vest in three equal installments on November 29, 2026, May 29, 2027, and November 29, 2027, subject to the terms of the award agreement.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for executives and directors to report changes in their beneficial ownership of company stock. These filings provide transparency into insider transactions, which can be a factor for investors to consider.

Stakeholder Impact

• Shareholders: Increased transparency into insider holdings and transactions.
• Employees: The RSU vesting schedule indicates ongoing compensation and incentive plans for management.
• Management: Ryan Crandall's continued direct ownership of a substantial number of shares aligns his interests with long-term company performance.

Next Steps

• Vesting of remaining RSUs on November 29, 2026, May 29, 2027, and November 29, 2027.

Key Dates

Keywords

MariMed Inc., MRMD, Form 4, SEC Filing, Stock Transaction, Ryan Crandall, Restricted Stock Units, Common Stock, Beneficial Ownership, Insider Trading